CWA
KNSA icon

Clarus Wealth Advisors’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Clarus Wealth Advisors’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-226
Closed -$3K – 377
2019
Q2 		$3K Hold
226
– – ﹤0.01% 542
2019
Q1 		$4K Buy
+226
New +$4.37K ﹤0.01% 606

Other funds holding KNSA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Clarus Wealth Advisors's KNSA Position: Q3 2019 in Review

Clarus Wealth Advisors sold out of Kiniksa Pharmaceuticals (KNSA) in Q3 2019, closing a stake of 226 shares — an estimated $3K sold.

Clarus Wealth Advisors first reported a position in KNSA in Q1 2019 and held it in 2 quarters. The position peaked at $4K in Q1 2019. 54 funds tracked by Wall St. Rank hold KNSA as of Q3 2019.

  • Clarus Wealth Advisors reported no remaining Kiniksa Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Clarus Wealth Advisors sold 226 Kiniksa Pharmaceuticals shares in Q3 2019, an estimated $3K.
  • Clarus Wealth Advisors first reported a position in Kiniksa Pharmaceuticals in Q1 2019 and held it in 2 quarters.
  • Clarus Wealth Advisors's Kiniksa Pharmaceuticals position peaked at $4K in Q1 2019.
  • 54 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q3 2019.

Based on Clarus Wealth Advisors's 13F filing for Q3 2019, filed 11 Oct 2019.